Dolutegravir (DTG), a drug previously feared to cause deformities in unborn children, is now the preferred HIV treatment option, even among women of reproductive age. PHOTO | FILE | NATION MEDIA GROUP
Dolutegravir (DTG), a drug previously feared to cause deformities in unborn children, is now the preferred HIV treatment option, even among women of reproductive age.
The World Health Organisation which is now updating its HIV therapy guidelines to show DTG as the first-line treatment option, recommended the drug based on its efficacy, tolerability and high genetic barrier to resistance.
